← All trials
NCT05571319
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 11, 2022
- Primary completion
- Mar 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- Oct 7, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stellenbosch UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- University of RochesterCollaborator
- Stellenbosch UniversityOverall official - principal investigator
- Stellenbosch UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.